Company intelligence / Profile preview
Lipid Therapeutics GmbH
Heidelberg, Baden-Württemberg, Germanylipid-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
LT-02, a delayed release formulation of Phosphatidylcholine, was designed as an add-on therapy to 5-aminosalicylic acid to improve the barrier function of the mucosal layer of the colon for ulcerative colitis treatment
- Therapeutic areas
- Gastroenterology
- Modalities
- PhospholipidsPhosphatidylcholine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Nestlé Health Science
Beyond the preview
Go deeper on Lipid Therapeutics GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lipid Therapeutics GmbH.